Compugen Ltd. appointed Gilead Halevy, Kinneret Livnat Savitzky and Sanford Zweifach to its board of directors.
The new directors will replace Dov Hershberg, who recently resigned, and Ruth Arnon and Michal Preminger, who are not standing for re-election.
Halevy is the founding member and general partner of Kedma Capital Partners. Savitzky is the interim CEO and a board member of FutuRX. Zweifach is the founder and the CEO of Nuvelution Pharma Inc.
Israel-based Compugen develops early stage immuno-oncology therapies, aimed at harnessing the immune system to eradicate cancer.
